Skip to main content
SpringerLink
Log in

PROMISE V2 — something new, something old and something borrowed

  • Comment
  • Published:

From Nature Reviews Urology

View current issue Sign up to alerts

Prostate-specific membrane antigen-PET has become a valuable diagnostic tool. The second version of the Prostate Cancer Molecular Imaging Standardized Evaluation framework is the next step towards a standardized evaluation and reporting system from primary staging to reassessment of advanced prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Maurer, T., Eiber, M., Schwaiger, M. & Gschwend, J. E. Current use of PSMA-PET in prostate cancer management. Nat. Rev. Urol. 13, 226–235 (2016).

    Article  CAS  PubMed  Google Scholar 

  2. European Association of Urology. EAU, EANM, ESTRO, ESUR, ISUP, SIOG Guidelines on Prostate Cancer. EAU https://uroweb.org/guideline/prostate-cancer (2023).

  3. Chang, S. S. et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 59, 3192–3198 (1999).

    CAS  PubMed  Google Scholar 

  4. Roberts, M. J. et al. Using PSMA imaging for prognostication in localized and advanced prostate cancer. Nat. Rev. Urol. 20, 23–47 (2023).

    Article  PubMed  Google Scholar 

  5. Fanti, S. et al. Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. Eur. J. Nucl. Med. Mol. Imaging 44, 1622–1635 (2017).

    Article  CAS  PubMed  Google Scholar 

  6. Rowe, S. P., Pienta, K. J., Pomper, M. G. & Gorin, M. A. Proposal for a structured reporting system for prostate-specific membrane antigen-targeted PET imaging: PSMA-RADS version 1.0. J. Nucl. Med. 59, 479–485 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Eiber, M. et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J. Nucl. Med. 59, 469–478 (2018).

    Article  PubMed  Google Scholar 

  8. Fanti, S. et al. Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 48, 469–476 (2021).

    Article  PubMed  Google Scholar 

  9. Gafita, A. et al. Novel framework for treatment response evaluation using PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J. Nucl. Med. 63, 1651–1658 (2022).

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Seifert, R. et al. Second version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur. Urol. 83, 405–412 (2023).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    Daniel Koehler

Authors
  1. Daniel Koehler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Koehler.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koehler, D. PROMISE V2 — something new, something old and something borrowed. Nat Rev Urol 20, 639–640 (2023). https://doi.org/10.1038/s41585-023-00807-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-023-00807-1

  • Springer Nature Limited

Search

Navigation